NasdaqGS:MLYSBiotechs
Will Phase 3 Launch-HTN Success and Conference Spotlight Change Mineralys Therapeutics' (MLYS) Narrative?
Mineralys Therapeutics recently highlighted that positive Phase 3 Launch-HTN data for lorundrostat in uncontrolled hypertension and chronic kidney disease were featured in an oral presentation at the European Meeting on Hypertension and Cardiovascular Protection 2026, following completion of six late-stage trials supporting its efficacy and safety profile.
The company also confirmed participation in the Jefferies 2026 Global Healthcare Conference, underscoring growing clinical and investor...
